Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development. by Popat, Reena J et al.
Popat, Reena J; Hakki, Seran; Thakker, Alpesh; Coughlan, Alice
M; Watson, Julie; Little, Mark A; Spickett, Corinne M; Lavender,
Paul; Afzali, Behdad; Kemper, Claudia; Robson, Michael G (2017)
Anti-myeloperoxidase antibodies attenuate the monocyte response to
LPS and shape macrophage development. JCI Insight, 2 (2). e87379.
DOI: https://doi.org/10.1172/jci.insight.87379
Downloaded from: http://researchonline.lshtm.ac.uk/4651872/
DOI: 10.1172/jci.insight.87379
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
1insight.jci.org   doi:10.1172/jci.insight.87379
R E S E A R C H  A R T I C L E
Conflict of interest: The authors have 
declared that no conflict of interest 
exists.
Submitted: March 2, 2016 
Accepted: December 12, 2016 
Published: January 26, 2017
Reference information: 
JCI Insight. 2017;2(2):e87379. 
doi:10.1172/jci.insight.87379.
Anti-myeloperoxidase antibodies 
attenuate the monocyte response to LPS 
and shape macrophage development
Reena J. Popat,1 Seran Hakki,1 Alpesh Thakker,2 Alice M. Coughlan,3 Julie Watson,4 Mark A. Little,3 
Corinne M. Spickett,2 Paul Lavender,4 Behdad Afzali,1 Claudia Kemper,1 and Michael G. Robson1
1Division of Transplant Immunology and Mucosal Biology, MRC Centre for Transplantation, King’s College London, Guy’s 
Hospital, Great Maze Pond, London, United Kingdom. 2School of Life & Health Sciences, Aston University, Aston Triangle, 
Birmingham, United Kingdom. 3Trinity Health Kidney Centre, Department of Clinical Medicine, Trinity College Dublin, St. 
James’ Hospital Campus, Dublin, Ireland. 4MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, King’s College 
London, Guy’s Hospital, Great Maze Pond, London, United Kingdom.
Introduction
Anti-neutrophil cytoplasmic antibody (ANCA) vasculitis is a systemic disease with clinical manifestations 
that include crescentic glomerulonephritis and pulmonary hemorrhage (1). The name ANCA vasculitis 
reflects the fact that it is characterized by autoantibodies against neutrophils (2). However, these autoanti-
bodies bind to the proteins myeloperoxidase (MPO) (3) or proteinase-3 (PR3) (4), which are found within 
granules not only in neutrophils but also in monocytes. The evidence that ANCAs are pathogenic comes 
from in vitro studies in which IgG from patients with anti-MPO or anti-PR3 antibodies activate neutrophils 
to undergo respiratory burst and degranulation, as first shown by Falk et al. (5) and confirmed by others 
(reviewed in ref. 6). In vivo support for the pathogenicity of  ANCA is provided by studies in which injec-
tion of  anti-MPO antibodies causes focal necrotizing crescentic glomerulonephritis in mice in a neutrophil-
dependent manner (7, 8). However, the effects of  ANCA on MPO- and PR3-expressing monocytes have 
received far less attention.
Monocytes and macrophages are present within early segmental lesions seen on renal biopsies from 
patients with ANCA vasculitis (9). Therefore, it is important to understand the effects of  ANCA on mono-
cytes, as this may contribute to both tissue inflammation and fibrosis. Fibrosis is an important clinical issue 
in both the lung and kidney, with glomerular sclerosis being closely linked to renal prognosis (10). There are 
data to suggest functional effects of  ANCA on monocytes. Ralston and colleagues described the produc-
tion of  IL-8 in response to PR3-ANCA (11) and O’Brien et al. recently described the production of  IL-1β, 
IL-6, and IL-8 by TNF-α–primed monocytes in response to MPO-ANCA but not to PR3-ANCA (12). 
Anti-neutrophil cytoplasmic antibody (ANCA) vasculitis is characterized by the presence of 
autoantibodies to myeloperoxidase and proteinase-3, which bind monocytes in addition to 
neutrophils. While a pathological effect on neutrophils is acknowledged, the impact of ANCA on 
monocyte function is less well understood. Using IgG from patients we investigated the effect of 
these autoantibodies on monocytes and found that anti-myeloperoxidase antibodies (MPO-ANCA) 
reduced both IL-10 and IL-6 secretion in response to LPS. This reduction in IL-10 and IL-6 depended 
on Fc receptors and enzymatic myeloperoxidase and was accompanied by a significant reduction 
in TLR-driven signaling pathways. Aligning with changes in TLR signals, oxidized phospholipids, 
which function as TLR4 antagonists, were increased in monocytes in the presence of MPO-
ANCA. We further observed that MPO-ANCA increased monocyte survival and differentiation to 
macrophages by stimulating CSF-1 production. However, this was independent of myeloperoxidase 
enzymatic activity and TLR signaling. Macrophages differentiated in the presence of MPO-ANCA 
secreted more TGF-β and further promoted the development of IL-10– and TGF-β–secreting CD4+ T 
cells. Thus, MPO-ANCA may promote inflammation by reducing the secretion of antiinflammatory 
IL-10 from monocytes, and MPO-ANCA can alter the development of macrophages and T cells to 
potentially promote fibrosis.
2insight.jci.org   doi:10.1172/jci.insight.87379
R E S E A R C H  A R T I C L E
Furthermore, production of  oxygen radicals by TNF-α–primed monocytes in response to MPO or PR3-
ANCA has been described (13). In addition to a pathogenic role for ANCA, cellular immunity is also con-
sidered to be important in ANCA vasculitis, with a role for effector CD4+ cells demonstrated in a murine 
model (14). Therefore, the effect of  monocytes and macrophages on CD4+ T cell activation and how this 
may be modified by ANCA is also an important question.
Here, we investigated the effect of  ANCA on human peripheral blood monocytes and found that 
MPO-ANCA impacted at least on 2 levels on monocyte function and that these functional deviations 
are likely to play a significant role in pathogenesis. MPO-ANCA reduced secretion of  antiinflammatory 
IL-10 by monocytes (and may hence further foster local inflammation) and also induced development of  
macrophages that instruct CD4+ T cells, which could contribute to the tissue fibrosis observed in vasculitis.
Results
MPO-ANCA decreases IL-10 and IL-6 production from monocytes in response to LPS. We examined the effect 
of  a large panel of  unselected MPO-ANCA, PR3-ANCA, and control IgG (11, 9, and 10 per group, 
respectively) on peripheral blood monocytes isolated from 5 healthy donors (see Supplemental Table 1  
for patient characteristics; supplemental material available online with this article; doi:10.1172/jci.
insight.87379DS1). To mirror the situation where ANCA bind monocytes in the context of  an inflam-
matory response, we stimulated monocytes with LPS and explored whether ANCA modulated the 
response to LPS. We measured a panel of  cytokines in the supernatant of  stimulated monocytes stimu-
lated with or without LPS in the presence of  control IgG or ANCA for 18 hours. After incubation with 
MPO-ANCA or control IgG but without LPS, none of  the indicated cytokines were detectable (data not 
shown). With LPS, while we did not observe an effect of  MPO-ANCA on IL-8 and MIP-1α production 
by monocytes, and its effects on TNF-α and IL-1β production were variable among donors, both IL-6 
and IL-10 were consistently and significantly decreased by MPO-ANCA across all 5 donors, with the 
most profound effect seen for IL-10. Addition of  PR3-ANCAs only had a consistent downmodulatory 
effect on IL-10, which was less marked than that of  MPO-ANCA (Figure 1). In summary, MPO-ANCA 
led to a consistent reduction in both IL-6 and IL-10 production by monocytes in response to LPS, 
while PR3-ANCA only reduced IL-10 but not IL-6 secretion in LPS-primed monocytes. Furthermore, 
we confirmed that this effect of  MPO-ANCA was due to MPO binding activity using affinity-purified 
antibody (Supplemental Figure 1.)
The effect of  MPO-ANCA on monocytes depends on Fc receptors and enzymatic MPO. Previously described 
effects of  ANCA on neutrophils have been reported to require Fc receptor binding and involve interaction 
with the β2 integrin CD18/CD11b, the complement receptor 3 (CR3) (15–17). We therefore examined if  
this was also the case for the observed effects of  MPO-ANCA on monocytes. We generated F(ab)2 frag-
ments from 4 MPO-ANCAs and 2 control IgGs and compared responses towards these F(ab)2 fragments 
with whole IgG (Figure 2A) using monocytes from 2 healthy donors. While the MPO-ANCA whole-IgG 
fraction elicited the expected reduction in IL-6 and IL-10, the addition of  MPO-ANCA F(ab)2 failed to 
have any effect on IL-6 or IL-10, strongly indicating that co-engagement of  the Fc receptors on the cell sur-
face is also needed for MPO-ANCA effects on monocytes. Interestingly, and in contrast with observations 
in neutrophils (17), co-engagement of  CR3 is not required for MPO-ANCA–induced reduction of  IL-6 
and IL-10, as blockade of  CD18 and/or CD11b did not impact on altered cytokine production (Figure 2B, 
experiments in 3 monocyte donors).
Importantly, the MPO-specific portion of  MPO-ANCA is equally critical to their monocyte modula-
tory effects, as is the presence of  enzymatically active MPO on monocytes. When we incubated mono-
cytes (± LPS) with exogenously added MPO protein, MPO-ANCA, or control IgG, in the presence or 
absence of  the specific MPO inhibitor AZD5904 (18), we found that both MPO-ANCA and exogenous 
MPO caused a reduction in IL-6 and IL-10 that is reversed by AZD5904 in a dose-dependent manner 
(Figure 3A and Supplemental Figure 2). The effects varied between the 4 monocyte donors tested. Over-
all, the reduction in IL-10 and IL-6 was not as marked for exogenous MPO as for MPO-ANCA, and the 
effect of  AZD5904 was stronger for exogenous MPO. These differences could potentially reflect differing 
local concentrations of  MPO at the monocyte cell membrane with MPO-ANCA and exogenous MPO, 
respectively. These data suggest that MPO-ANCA is inhibiting IL-6 and IL-10 release in response to 
LPS by a mechanism dependant on the increased enzymatic activity of  MPO. To assess our hypothesis 
that MPO-ANCA may tether MPO released by activated monocytes to the cell surface, we assessed the 
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surface expression of  MPO by flow cytometry in the presence of  MPO-ANCA or control IgG and also 
measured the concentration of  MPO in the supernatant of  cultured activated monocytes. Addition of  
MPO-ANCA indeed led to a decrease in free MPO in the supernatant (Figure 3B), with a concomitant 
increase in cell surface MPO expression (Figure 3C). This increase in cell surface MPO expression did 
not reflect increased monocyte activation as, in the same experiments, expression of  CD11b and CD14 
was not higher in MPO-ANCA compared with control IgG–treated samples (data not shown). We also 
detected immune complexes containing MPO and IgG in the supernatants of  monocytes cultured with 
MPO-ANCA, which further supported our hypothesis (Supplemental Figure 3). In summary, these data 
suggest that MPO-ANCA may anchor MPO to the surface of  the monocyte via Fc receptor binding and 
thereby facilitate or increase the action of  MPO enzyme on the cell surface.
Figure 1. MPO-ANCA decreases IL-10 and IL-6 production from monocytes in response to LPS. Cytokine production from peripheral blood monocytes 
incubated for 18 hours with 100 ng/ml LPS and anti-myeloperoxidase antibodies (MPO-ANCA), anti–proteinase-3 antibodies (PR3-ANCA), or control 
IgG (n = 9–11 of each type). Experiments were performed in 5 different healthy monocyte donors. Not activated (NA; no LPS) and LPS-only treated 
cells are shown in the same column, with the LPS-only data being the higher point in all cases. All other groups contained LPS in addition to the 
stated type of IgG preparation. *P < 0.05, **P < 0.01, ***P < 0.001 by 1-way ANOVA and Dunnett’s post-test with control IgG as the control group. 
Error bars represent mean ± SEM. For a given monocyte donor, n is the number of IgG preparations from different individuals. They are not technical 
replicates or repeated measures of the same IgG samples.
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MPO-ANCA inhibits TLR signaling pathways. IL-6 has been shown to promote IL-10 secretion in T cells 
(19, 20) and we therefore assessed whether the reduction in IL-10 production by monocytes upon ANCA-
MPO addition was secondary to the reduction in IL-6. However, in monocytes IL-6 seems not to drive 
IL-10 production, as addition of  exogenous IL-6 to cultures during activation failed to increase IL-10 
production (Figure 4A).
Figure 2. The effect of MPO-ANCA on monocytes depends on Fc receptors but not CD11b or CD18. (A) IL-10 and IL-6 produc-
tion from peripheral blood monocytes incubated for 18 hours with LPS and anti-myeloperoxidase antibodies (MPO-ANCA) 
(n = 4) or control IgG (n = 2) compared with the effect of F(ab)2 preparations of the same IgG preparations. NA, not activated 
(no LPS). All other groups contained LPS in addition to the stated type of IgG preparation. (B) IL-10 and IL-6 production from 
peripheral blood monocytes incubated for 18 hours with LPS and MPO-ANCA (n = 4) or control IgG (n = 4) in the presence of 
CD11b- or CD18-blocking antibodies. We also tested the effect of combined CD11b and CD18 blockade, with controls shown 
for no-antibody control and isotype-control monoclonal. ns, not significant. *P < 0.05, **P < 0.01, ***P < 0.001 by 2-tailed 
Student’s t test. Error bars represent mean ± SEM. For a given monocyte donor, n is the number of IgG preparations from 
different individuals. They are not technical replicates or repeated measures of the same IgG samples.
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To define the pathways driven by 
MPO-ANCA leading to altered cyto-
kine production in monocytes, we 
performed gene expression microar-
rays on monocytes treated with LPS 
and MPO-ANCA (n = 3) or control 
IgG (n = 3) for 1 or 6 hours. At 1 
hour, we observed only 12 genes that were differentially expressed between the groups, with a threshold 
of  1.75 in either direction. However, at 6 hours this rose to 566 genes (Figure 4B, with genes listed in 
Supplemental Table 2). Functional annotation analysis revealed that the altered gene expression profile was 
enriched overall for biological processes involved in immune cell activation and inflammatory responses 
(Figure 4C). Likewise, these analyses demonstrated that one of  the most prominently affected KEGG 
pathways is in genes regulated by TLR signaling (Figure 4D). A gene set enrichment analysis (GSEA) was 
carried out (21, 22), comparing expression of  all genes expressed by MPO-ANCA–treated and control 
IgG–treated monocytes in our arrays for enrichment of  genes in the KEGG TLR signaling pathway, and 
we found that these genes were preferentially inhibited in the MPO-ANCA–treated cells (Figure 4E). The 
leading edge or core genes inhibited in this gene set are shown in Figure 4F. Specific examination of  the 
expression of  genes known to be regulated by LPS or by the Myd88 pathways using ingenuity pathway 
analysis (IPA) confirmed a profound inhibitory effect on these genes engendered by the presence of  MPO-
ANCA relative to control IgG. Z scores for LPS and Myd88 were –4.96 and –2.22, respectively, and overlap 
P values for LPS and Myd88 were 1.87 × 10–58 and 1.56 × 10–9, respectively (see also Supplemental Figures 4 
Figure 3. The effect of MPO-ANCA on 
monocytes depends on enzymatic 
MPO. (A) The effect of varying doses 
of the myeloperoxidase (MPO) inhibi-
tor AZD5904 on IL-6 and IL-10 produc-
tion from peripheral blood monocytes 
incubated for 18 hours with LPS and 
anti-myeloperoxidase antibodies (MPO-
ANCA) (n = 2) or control IgG (n = 2), with 
the experiment performed in 4 different 
monocyte donors. Exogenous MPO (2 μg/
ml) with and without AZD5904 (400 nM) 
was also added to monocytes incubated 
with LPS. Supplemental Figure 2 shows 
a dose-response curve for AZD5904 and 
exogenous MPO. (B) MPO measured by 
ELISA in the supernatant of peripheral 
blood monocytes incubated for 18 hours 
with LPS and MPO-ANCA (n = 10) or 
control IgG (n = 10). NA, not activated 
(no LPS). (C) Flow cytometry histograms 
of MPO on peripheral blood monocytes 
incubated for 2 hours with LPS and MPO-
ANCA (n = 2, mean fluorescence intensi-
ties [MFIs] 160 and 206) or control IgG (n 
= 2, MFIs 100 and 99). MPO expression 
was measured in 2 additional monocyte 
donors under the same conditions and 
results were similar. Donor 2: MPO-ANCA 
(n = 2, MFIs 617 and 660) or control IgG 
(n = 2, MFIs 416 and 423). Donor 3: MPO-
ANCA (n = 2, MFIs 249 and 259) or control 
IgG (n = 2, MFIs 219 and 192). ***P < 0.001 
by 2-tailed Student’s t test. Error bars rep-
resent mean ± SEM. For a given monocyte 
donor, n is the number of IgG preparations 
from different individuals. They are not 
technical replicates or repeated measures 
of the same IgG samples.
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and 5). Therefore, MPO-ANCA caused a general reduction in normal LPS/TLR–triggered TLR-mediated 
pathways regulating monocyte activation, which as a net result affected at minimum the production of  IL-6 
and IL-10 by these cells. 
MPO-ANCA generates oxidized phospholipids. Since MPO is a powerful oxidant that can oxidize phos-
pholipids to form a variety of  products (23, 24), and under certain conditions oxidized phospholipids are 
antagonists of  LPS-induced TLR4 activation (25–27), we hypothesized that MPO-ANCA might bind 
released MPO at the plasma membrane and lead to the generation of  oxidized phospholipids. These 
may be responsible for blocking the effect of  LPS. To support this hypothesis, we investigated whether 
incubation with MPO-ANCA altered the phospholipid profile of  LPS-stimulated monocytes and led to 
increased generation of  oxidized phospholipids. We incubated monocytes with LPS and MPO-ANCA (n 
= 3) or control IgG (n = 3) for 18 hours, extracted phospholipids, and assessed the phosphatidylcholine 
(PC) profile using liquid chromatography/mass spectrometry (LCMS). Treatment with MPO-ANCA did 
not affect the native phospholipid profile, and a variety of  chain-shortened oxidized phospholipids were 
Figure 4. MPO-ANCA inhibits TLR signaling pathways. (A) The effect of exogenous IL-6 on IL-10 secretion from peripheral blood monocytes incubated for 
18 hours with LPS and anti-myeloperoxidase antibodies (MPO-ANCA) (n = 2) or control IgG (n = 2). NA, not activated (no LPS). All other groups contained 
LPS in addition to the stated type of IgG preparation. (B) Volcano plot comparing monocytes activated for 6 hours with either MPO-ANCA (n = 3) or control 
IgG (n = 3) in the presence of LPS. Threshold for significance is 1.75-fold change in either direction and P < 0.05. The 566 differentially expressed transcripts 
are highlighted in orange (listed in Supplemental Table 2). (C and D) Gene Ontology (C) and KEGG pathway (D) functional annotation analysis of the dif-
ferentially expressed genes, showing the top 6 terms for each. (E) Gene set enrichment analysis (GSEA) for enrichment of genes in the KEGG TLR signaling 
pathway between MPO-ANCA–treated and control IgG–treated monocytes. (F) Heat map of the core-enriched genes from the GSEA in E. NES, normalized 
enrichment score; FDR, false discovery rate. In panel A, n is the number of IgG preparations from different individuals. They are not technical replicates or 
repeated measures of the same IgG samples.
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observed in both control IgG– and MPO-ANCA–incubated monocytes (Supplemental Figure 6). Figure 
5A shows the relative intensities of  8 oxidatively modified and lyso-PC species that were found to be most 
abundant. Supplemental Table 3 gives assignments of  the PCs based on their mass-to-charge ratio (m/z) 
and retention time. The data are presented as a percentage of  the signal of  the saturated phospholipid 
Figure 5. MPO-ANCA generates oxidized phospholipids. (A) The most abundant oxidized phospholipids extracted from peripheral blood monocytes 
incubated for 18 hours with LPS and anti-myeloperoxidase antibodies (MPO-ANCA) (n = 3) or control IgG (n = 3). The data are presented as a percentage of 
the intensity of the native saturated phospholipid dipalmitoylphosphatidylcholine at m/z 734 in each sample. *P < 0.05 by 2-tailed Student’s t test). (B) 
Extracted ion chromatograms (XICs) for the control IgG–treated (n = 3) and MPO-ANCA–treated (n = 3) samples, showing the intensity of the long-chain 
oxidized phospholipid species at m/z 828.8 eluting at ~29.5 minutes, ahead of nonoxidized species of the same m/z ratio. The labels above the peaks 
indicate their respective area as calculated by Peakview software. Based on these characteristics, the early eluting species at m/z 828.8 was identi-
fied (arrow) as 1-palmitoyl-2-(epoxyisoprostane E2)-sn-glycero-3-phosphocholine (PEIPC). The XICs were prepared with a window of 0.7 Da and without 
smoothing. (C) Surface E06 staining on peripheral blood monocytes incubated for 18 hours with LPS and MPO-ANCA (n = 3) or control IgG (n = 3). (D) Mean 
fluorescence intensity (MFI) data from the experiment shown in C and 2 other monocyte donors to give 3 monocyte donors in total. The effect of adding 
the MPO inhibitor AZD5904 (4 μM) to MPO-ANCA–treated monocytes is also shown. Control IgG was compared with MPO-ANCA using a 2-tailed Student’s 
t test. MPO-ANCA was compared with MPO-ANCA + AZD5904 using a 2-tailed paired Student’s t test (with lines indicating paired samples). *P < 0.05. 
Error bars represent mean ± SEM. For a given monocyte donor, n is the number of IgG preparations from different individuals. They are not technical repli-
cates or repeated measures of the same IgG samples.
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dipalmitoyl PC at m/z 734, as this is relatively resistant to oxidative damage. This approach allows cor-
rection for variability in the total phospholipid content of  the samples and provides a better assessment 
of  the levels of  oxidized species within the total phospholipid pool. For most of  the oxidatively modified 
and lyso-PC species, there was no significant difference in their relative abundance between control IgG–
treated and MPO-ANCA–treated monocytes, and the levels of  some commonly observed chain-shortened 
oxidized PCs such as 1-palmitoyl-2-oxovaleroyl-PC (POVPC) and 1-palmitoyl-2-glutaroyl-PC (PGPC) 
were on the limit of  detection. However, it was found that a PC species at m/z 828.8 eluting in the range 
of  long-chain oxidized phospholipids was significantly higher in MPO-ANCA–treated monocytes (Fig-
ure 5A). Figure 5B shows extracted ion chromatograms (XICs) for m/z 828.8 for each of  the 6 samples. 
This phospholipid was tentatively identified as 1-palmitoyl-2-(5,6-epoxyisoprostane E2)-PC (PEIPC). We 
next investigated the presence of  oxidized phospholipids using flow cytometry. We reasoned that this 
technique was more accessible, allowing us to study multiple donors. Having found some oxidized phos-
pholipids at the limit of  detection with MS, it could also be more sensitive, as the oxidized phospholipid 
is being detected directly on the cell surface. E06 is a monoclonal antibody that binds 1-palmitoyl-2-(5′-
oxo-valeroyl)-sn-glycero-3-phosphocholine (POVPC) (28). In experiments with 3 monocyte donors, we 
found that MPO-ANCA significantly increased E06 staining in LPS-primed monocytes (Figure 5, C and 
D). This inhibition of  this effect by AZD5904 was statistically significant in 1 donor with a trend in 2 oth-
ers (Figure 5D), suggesting a role for enzymatic MPO. Thus, using 2 different techniques, we have found 
evidence of  oxidized phospholipid, which is increased in MPO-ANCA–treated monocytes and can func-
tion as a potential TLR4 antagonist, and hence explain the reduced TLR gene expression signature in the 
presence of  MPO-ANCA (Figure 4).
MPO-ANCA causes an increase in monocyte survival and differentiation to macrophages by increasing CSF-1 
expression. While monitoring cultures we noticed that monocytes treated with MPO-ANCA were more 
abundant than those treated with control IgG. Based on these observations, we next explored the effect of  
MPO-ANCA on monocyte survival and differentiation. To avoid the potential skewing (M1 or M2) effects 
of  growth factor addition, we performed these experiments in the absence of  LPS and in the presence of  
10% human type AB serum, which has been shown to support monocyte-to-macrophage differentiation 
in cultures in an unbiased fashion (29). Using 10 MPO-ANCA and 10 control IgG that were also used in 
the previous experiments, we found that MPO-ANCA significantly increased cell survival after 6 days in 
culture using monocytes from 2 distinct donors (Figure 6A). Since macrophage colony stimulating factor 
(M-CSF; CSF-1) is a key survival and differentiation factor for monocytes and macrophages, we measured 
production of  this factor by monocytes. We found indeed a marked increase in CSF1 mRNA expression 
in the presence of  MPO-ANCA compared with control IgG (Figure 6B). The importance of  CSF-1 is 
supported by the finding that addition of  the CSF-1 receptor inhibitor GW2580 caused a dose-dependent 
reversal of  the increase in cell numbers at day 6 (Figure 6C). We next assessed whether the MPO-ANCA/
CSF-1–driven effects on monocyte proliferation depended on enzymatic MPO, as we had found this to be 
the case for the reduction in IL-6 and IL-10. The MPO inhibitor AZD5904 did not prevent the increase in 
CSF1 mRNA expression due to MPO-ANCA, which in fact was greater (Figure 6B). Despite the increase 
in CSF1 expression, AZD5904 caused a decrease in macrophages at day 6 in the presence of  MPO-ANCA 
(Figure 6D). This suggests that AZD5904 has inhibitory effects on monocyte/macrophage differentiation, 
unrelated to CSF1. Since MPO-ANCA had been shown to interfere with TLR signaling pathways (Figure 
4), and human serum contains endogenous ligands for TLR2 and TLR4, we assessed if  the observed 
effect on differentiation and survival was the result of  TLR4 antagonism. However, combined blockade of  
TLR2 and TLR4 with neutralizing Abs had no effect on cell survival (Figure 6E). Overall, these data show 
a marked increase in cell proliferation after peripheral blood monocytes are incubated for 6 days with 
MPO-ANCA compared with control IgG. The effect is largely due to an MPO-ANCA–mediated increase 
in CSF-1 secretion, which itself  seems independent of  MPO enzymatic activity.
Macrophages differentiated in the presence of  MPO-ANCA express increased CD206, secrete TGF-β, and promote 
CD4+ T cell production of  IL-10 and TGF-β. To explore the functional consequences of  the effect on MPO-
ANCA during macrophage maturation in human serum, we measured cytokines in the supernatant at day 
6 in culture. IL-10, IFN-γ, IL-17A, IL-2, IL-4, IL-6, and TNF-α were undetectable (data not shown). How-
ever, TGF-β was detected at levels above that found in the culture medium, and was specifically increased 
in the presence of  MPO-ANCA (Figure 7A). Furthermore, expression of  the macrophage marker CD206 
was induced in both MPO-ANCA– and control IgG–treated cultures but was higher with MPO-ANCA 
9insight.jci.org   doi:10.1172/jci.insight.87379
R E S E A R C H  A R T I C L E
(Figure 7B). This difference in CD206 expression was apparent after only 3 days in culture (Supplemental 
Figure 7). This observation, together with the lower CD80 expression induction we observed in MPO-
ANCA–treated monocytes (Figure 7B), suggests that macrophages maturing in the presence of  MPO-
ANCA have an M2 phenotype in keeping with the role that we have shown for CSF-1 (Figure 6), which is 
known to favor M2 macrophage skewing (30).
Patients with vasculitis have T cells within affected glomeruli (31) and also changes in and/or persis-
tence of  local Th1 and Th2 responses (32). Therefore, to investigate potential effects of  MPO-ANCA–
exposed macrophages on CD4+ T cells, we transferred supernatants from antibody-treated macrophages 
to CD4+ T cells during anti-CD3 and anti-CD28 stimulation and measured cytokine production by 
stimulated CD4+ T cells. While IL-17A was not consistently affected by macrophage-derived factors 
(Supplemental Figure 8) and IL-4 was not detected (not shown), we observed a consistent decrease in 
IFN-γ production accompanied with an increase in IL-10 specifically in T cells activated in the presence 
of  supernatants from MPO-ANCA–treated macrophages, with a statistically significant and persistent 
increase in the IL-10 to IFN-γ ratio (Figure 7C). In addition, TGF-β levels in the T cell supernatants 
were increased when the T cells were stimulated in the presence of  supernatants from MPO-ANCA–
treated macrophages (Figure 7C). The TGF-β levels were higher than those found in the macrophage 
supernatants or the basal T cell medium and so they reflected production from T cells. Overall these 
data show that in the presence of  MPO-ANCA and AB serum, peripheral blood monocytes differenti-
ate into macrophages with an M2-like phenotype that express high levels of  CD206, reduced CD80, 
and secrete increased TGF-β. Furthermore, such MPO-ANCA–conditioned macrophages induce IL-10 
and TGF-β production in activated CD4+ T cells, which could potentially increase fibrosis.
Figure 6. MPO-ANCA causes an increase in monocyte survival and differentiation to macrophages by increasing CSF-1 expression. (A) Number of cells 
remaining after culturing peripheral blood monocytes with 10% human type AB serum and anti-myeloperoxidase antibodies (MPO-ANCA) (n = 10) or 
control IgG for 6 days (n = 10) without LPS. Results are shown for 2 healthy monocyte donors. (B) CSF-1 gene expression in peripheral blood monocytes 
after 18 hours in culture MPO-ANCA or control IgG, with and without the MPO inhibitor AZD5904 (400 nM). (C) The effect of varying concentrations of the 
CSF-1 receptor inhibitor GW280 on cell number in the presence of MPO-ANCA (n = 2) or control IgG (n = 2). (D) The effect of the MPO inhibitor AZD5904 
(400 nM) on cell number after peripheral blood monocytes were cultured for 6 days in 10% AB serum in the presence of MPO-ANCA (n = 3) or control IgG (n 
= 3). (E) The effect of TLR2/4 blockade on cell number after 6 days in 10% AB serum in the presence of MPO-ANCA (n = 3) or control IgG (n = 3). *P < 0.05, 
***P < 0.001 by 2-tailed Student’s t test. Error bars represent mean ± SEM. For a given monocyte donor, n is the number of IgG preparations from different 
individuals. They are not technical replicates or repeated measures of the same IgG samples.
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Discussion
We have discovered some effects of  MPO-ANCA on human monocytes with potential implications 
for pathogenesis in ANCA vasculitis. These include a marked reduction in both IL-6 and IL-10 in 
response to TLR4 stimulation in monocytes, which depends on MPO enzymatic activity and is pos-
sibly mediated by an MPO-driven increase in oxidized phospholipids. MPO catalyzes oxidation reac-
tions and can produce a variety of  oxidized lipids with bioactive effects (33). The PC species at m/z 
828.8 that was increased in MPO-ANCA–treated monocytes was tentatively identified as PEIPC, which 
Figure 7. Macrophages differentiated in the presence of MPO-ANCA express increased CD206, secrete TGF-β, and promote CD4+ T cell production of IL-10 
and TGF-β. (A) TGF-β in the supernatants of macrophages that developed from monocytes after 6 days in culture with 10% human type AB serum and 
anti-myeloperoxidase antibodies (MPO-ANCA) (n = 3) or control IgG (n = 3). Experiments were performed with monocytes from 2 donors. (B) Expression 
of CD206 and CD80 on macrophages that developed after 6 days in culture with 10% AB serum with control IgG (n = 2) or MPO-ANCA (n = 2). Experiments 
were performed with monocytes from 2 healthy donors with histograms shown for 1 donor. CD206 mean fluorescence intensities (MFIs) for donor 1 were 
3,182 and 3,227 (MPO-ANCA) and 2,202 and 2,624 (Control IgG). CD206 MFIs for donor 2 were 33,466 and 33,287 (MPO-ANCA) and 20,565 and 8,357 (Control 
IgG). CD80 MFIs for donor 1 were 222 and 228 (MPO-ANCA) and 419 and 465 (Control IgG). CD80 MFIs for donor 2 were 1,113 and 1,213 (MPO-ANCA) and 
2,413 and 3,806 (Control IgG). (C) Peripheral blood CD4+ T cells were stimulated for 3 and 5 days with anti-CD3 and anti-CD28 in the presence or absence 
of added supernatant from monocyte/macrophages cultured with no added IgG (n = 1), control IgG (n = 3), or MPO-ANCA (n = 3). The ratio of IL-10 to IFN-γ 
is indicated, with TGF-β concentrations. Concentrations of IL-10, IFN-γ, and IL-17A are shown in Supplemental Figure 8. Experiments were performed with 
CD4+ T cells from 2 donors, each using macrophage supernatants from different experiments. *P < 0.05, **P < 0.01, ***P < 0.001 by 2-tailed Student’s t 
test. Error bars represent mean ± SEM. For a given monocyte donor, n is the number of IgG preparations from different individuals. They are not technical 
replicates or repeated measures of the same IgG samples. SN, supernatant.
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has been reported previously to be generated in LPS-stimulated monocytes and neutrophils (34). We 
also demonstrated an increase in POVPC using the monoclonal antibody E06. Oxidized phospholip-
ids have been shown to have a wide variety of  bioactivities, including effects on leukocytes. It is now 
well established that these effects can be both pro- and antiinflammatory, and depend both on the 
specific oxidized phospholipid and the cell type (23). One important antiinflammatory mechanism of  
oxidized PAPC products is through inhibition of  TLR2 and TLR4 signaling, as they interfere with LPS 
and lipopeptide signaling via LBP, sCD14, mCD14, and MD2 (25–27, 35). It has been reported previ-
ously that both PEIPC and POVPC, similarly to other oxidized phospholipids, can inhibit LPS-induced 
E-selectin expression in endothelial cells, at concentrations approximately 10-fold lower than those that 
induce IL-8 production (27, 36). Interestingly, studies on the role of  oxidized phospholipids in immune 
responses to leprosy have found that PEIPC was able to inhibit human monocyte function in a TLR2-
dependent manner (37). PEIPC is indeed one of  the most abundant esterified products produced during 
oxidation of  PAPC in vitro, and has also been detected as a major product in inflammatory lesions, as 
would be found in ANCA vasculitis (24).
Evidence was found for the presence of  POVPC on the cell surface by flow cytometry and for free 
PEIPC in whole-cell extracts, but this does not preclude the occurrence or importance of  other oxidized 
phospholipids or oxidized phospholipid adducts. Currently, it is not clear why a significant increase was 
only observed for a single oxidized species using MS. If  MPO-ANCA tethers MPO to the cell surface, this 
would cause localized oxidation that might not be readily apparent in extracts of  total cellular phospholip-
ids. In addition, some oxidized phospholipids can be interconverted and further metabolized, which may 
also have contributed to variability in the analysis and limited the number of  statistically significant find-
ings. We would also stress that we are not excluding that MPO-ANCA also affects additional pathways that 
contribute to the observed phenotype.
The effects of  IL-6 are difficult to predict. The biology of  IL-6 is complex and this cytokine has 
both proinflammatory and antiinflammatory effects mediated by classical and by trans-signaling via a 
soluble receptor (38). For example IL-6 regulates neutrophil recruitment to inflammatory sites by promot-
ing granulopoiesis (39), but following neutrophil recruitment and soluble IL-6 receptor shedding, IL-6 
signaling on stromal cells will limit neutrophil influx (40). In contrast, IL-10 is undeniably an antiinflam-
matory cytokine and moreover the reduction in its level was more pronounced than that seen for IL-6. 
Many mechanisms are in place to prevent exaggerated inflammatory responses and IL-10 has proved to 
be an essential factor in this protection (41). For example, animals that are genetically deficient in IL-10 
or are treated with antibodies that neutralize IL-10 die rapidly when infected with pathogens due to the 
overproduction of  proinflammatory cytokines rather than a lack of  control of  infection (42, 43). In the 
context of  tissue inflammation in ANCA vasculitis, cells such as tissue macrophages, dendritic cells, epi-
thelial cells, and renal mesangial cells do not contain MPO and will not be affected by MPO-ANCA. 
However, they will be influenced by cytokines released locally by monocytes. A reduction in monocyte 
IL-10 would therefore be expected to increase the responsiveness of  these cells to stimulation by TLRs and 
other inflammatory stimuli and to lead to an exaggerated inflammatory response. This protective effect of  
IL-10 is demonstrated in the context of  renal inflammation in the unilateral ureteral obstruction model. 
More severe inflammation develops in the kidney of  mice lacking IL-10 compared with wild-type controls 
(44). Overall, the dominant effect of  MPO-ANCA on monocytes is a reduction in IL-10 secretion, which 
would be expected to promote inflammation and disease in patients.
The TLR4 inhibition observed is specific, as demonstrated by the lack of  effect on cytokines other 
than IL-6 and IL-10. Interesting parallels exist between our work and recent data on monocytes in 
patients with chronic recurring multifocal osteomyelitis (CRMO) (45, 46). CRMO is an autoinflamma-
tory condition characterized by sterile inflammation in bone with systemic symptoms. In these patients, 
monocytes fail to produce IL-10 in response to stimulation with LPS (45), whereas production of  proin-
flammatory cytokines including TNF-α and IL-6 are unaffected. Monocytes from CRMO patients had 
impaired ERK1/2 activation and sp-1 recruitment to the IL-10 gene promoter (46). The phenotype of  
CRMO monocytes was reproduced by treatment with an ERK1/2 inhibitor at a concentration having a 
submaximal effect. At this concentration, IL-10 was reduced with no effect on TNF-α. The molecular 
mechanism leading to reduced ERK1/2 activation and sp-1 expression was not established in this study. 
However, this previous work does demonstrate that attenuated TLR4 signaling can lead to a reduction 
in IL-10, with no effect seen on proinflammatory cytokines.
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We also showed that MPO-ANCA causes an increase in survival and differentiation of  monocytes 
to M2-like macrophages in culture primarily through an increase in CSF-1 production. Macrophages 
play an important role in wound healing as well as fibrosis. They stimulate and activate fibroblasts to 
produce extracellular matrix proteins (reviewed in ref. 47). It is increasingly recognized that the phe-
notype of  macrophages does not fall into a simple M1 or M2 category (48). However, the increased 
expression of  CD206 and reduced CD80, with TGF-β secretion, suggests that the macrophages fit most 
closely with an M2-like phenotype, consistent with their induction by an increased concentration of  
CSF-1 (49). TGF-β has been established for over a decade as a key cytokine that promotes the induction 
of  regulatory T cells (50), and this has been confirmed by subsequent reports. There has been relatively 
little work on the induction of  regulatory T cells by macrophages. In mice, macrophages polarized to 
secrete TGF-β have been shown to inhibit adriamycin-induced nephrosis by a mechanism that includes 
the induction of  regulatory T cells (51). A further report has also shown that human M2 macrophages 
can induce CD4+ T cells with a regulatory phenotype (52). In both of  these examples, the mechanism of  
suppression was thought to require cell contact, whereas we have shown the effect of  a soluble factor in 
the supernatant. Nonetheless, there are parallels with our data suggesting that M2 macrophages, gener-
ated from monocytes incubated with MPO-ANCA, limit T cell activation via TGF-β.
Our current data suggest that macrophages generated from MPO-ANCA–stimulated monocytes act 
to limit the activation of  IFN-γ–producing CD4+ T cells and promote the switch to an IL-10–producing 
phenotype. Over the past few years we have described the life cycle of  a Th1 CD4+ cell as it changes 
from producing predominantly IFN-γ to producing both IFN-γ and IL-10 and then to producing pre-
dominantly IL-10 and acquiring suppressive capacity, with switching enhanced by ligation of  CD46 
(53). This represents a key pathway in the life cycle of  Th1 cells as they switch from an inflammatory 
to a regulatory phenotype. These IL-10–secreting CD4+ T cells may be similar to, if  not the same as, 
those that have been called induced regulatory T cells (54). We have found that CD46-activated CD4+ 
T cells indeed express increased TGF-β (C Kemper, unpublished data). We now show that CD4+ T cells 
activated in the presence of  supernatants from MPO-ANCA–stimulated monocytes/macrophages also 
produce TGF-β. T cells have been shown to be important in both pulmonary (55) and renal fibrosis (56), 
with several potential mechanisms that have not been fully defined. A direct effect of  TGF-β produced 
by T cells is one possibility and we have shown how this may be promoted by MPO-ANCA via its 
actions on monocytes. Effects of  TGF-β include a direct stimulation of  fibroblasts to cause differentia-
tion into myofibroblasts with concomitant collagen secretion (57). The amount of  fibrosis remaining 
in vital end organs such as the lung and kidney is a major prognostic factor for patients with ANCA 
vasculitis (10).
Throughout the experiments presented in this paper, we have used IgG from healthy donors as a con-
trol. We found that F(ab)2 MPO-ANCA failed to have any effect on IL-6 and IL-10 secretion (Figure 2A) 
and that immune complexes were formed by MPO-ANCA (Supplemental Figure 3). Therefore, an addi-
tional informative control would have been to use similarly sized immune complexes with an irrelevant 
antigen. Further work will be required to assess if  at least some of  the effects we have described are repro-
duced by immune complexes containing other antigens.
In summary, we have shown 2 effects of  MPO-ANCA on monocytes with implications for disease in 
patients. These are firstly, a reduction in IL-10 in response to LPS stimulation, potentially due to inhibition 
of  TLR signaling by oxidized phospholipids, which are known to be TLR4 antagonists. We acknowledge 
that, although our data are consistent with this model, we have not proved that oxidized phospholipids are 
acting as TLR4 antagonists in this context. Secondly, MPO-ANCA, by stimulating CSF-1 production, pro-
motes monocyte survival and differentiation to macrophages, which instruct the generation of  regulatory T 
cells that produce IL-10 and TGF-β and may promote fibrosis. Further characterization of  the phenotype 
of  the human macrophages induced by MPO-ANCA, and in vivo work in murine models, will clarify the 
potential clinical importance of  both of  these effects.
Methods
Purification of  IgG from patients and controls and generation of  F(ab)2 fragments. Blood or plasma exchange fluid 
was obtained from patients with ANCA vasculitis or healthy controls and plasma stored at –80°C. Fibrino-
gen was precipitated by adding 18 g/100 ml of  sodium chloride and IgG was purified with protein G chro-
matography (GE Healthcare). The endotoxin concentration in the final IgG preparations was measured 
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by Lonza using a LAL kinetic chromogenic assay. For all 30 polyclonal IgGs used, the endotoxin was less 
than 0.25 eU/250 μg IgG. The concentration of  IgG used for all neutrophil and monocyte assays was 250 
μg/ml. To generate F(ab)2 fragments, whole IgG was buffer exchanged using PD10 columns into 20 mM 
sodium acetate and digested using immobilized pepsin (Thermo Fisher Scientific). The F(ab)2 fragments 
were separated from undigested IgG using protein A affinity columns (GE Healthcare). SDS-PAGE dem-
onstrated the purity of  whole IgG and the F(ab)2 fragments. Before all assays, IgG preparations were cen-
trifuged at 16,000 g for 30 minutes at 4°C to remove aggregates. In mechanistic experiments where smaller 
numbers of  IgG samples were used, these were taken from this full set of  30 samples.
Monocyte and CD4+ T cell isolation. Peripheral blood mononuclear cells of  healthy human controls were iso-
lated from heparinized whole blood by Ficoll-Paque (GE Healthcare) density gradient centrifugation. Periph-
eral blood mononuclear cells were aspirated. Monocytes and CD4+ T cells were isolated using magnetic 
CD14 and CD4 microbeads, respectively (Miltenyi Biotec), according to the manufacturer’s instructions.
Monocyte culture. Monocytes were resuspended at 1 × 106 cells/ml in RPMI 1640 media containing 10% 
FBS (Sigma-Aldrich) for 18-hour cultures, or human type AB serum (PAA Labs) for 6-day cultures, and 1% 
penicillin/streptomycin (Thermo Fisher Scientific). Monocytes were cultured in 48-well plates for selective 
time periods with or without 100 ng/ml LPS (from Escherichia coli, O55:B5, Sigma-Aldrich, L6529) and 
polyclonal ANCA or control IgG at a final concentration of  250 μg/ml. The cells were incubated at 37°C 
for varying time points, after which supernatants were collected and cell counts were performed. When 
used, inhibitors were added prior to the addition of  ANCA or control IgG. MPO inhibitor AZD5904 (pro-
vided by AstraZeneca) and CSF-1 receptor inhibitor GW2580 (BioVision) were reconstituted in DMSO, 
with a final DMSO concentration of  less than 0.1%. Blocking antibodies were anti-CD11b clone ICRF44 
(10 μg/ml), anti-CD18 clone TS1/18 (10 μg/ml) (both Biolegend), and control IgG1 clone 107.3 (BD 
Biosciences). TLR2/4 blocking and control antibodies were from Invivogen (neutralizing TLR2 Ab clone 
B4H2, neutralizing TLR4 Ab clone W7C11, and isotype control clone T9C6) and BD Biosciences (isotype 
control clone 107.3) used at 10 μg/ml each. MPO was detected in monocyte supernatants by ELISA (R&D 
Systems DuoSet) according to the manufacturer’s instructions. MPO added to the culture in the experiment 
shown in Figure 5 was from Calbiochem. Recombinant IL-6 was from Biolegend. For macrophage pheno-
typing, cells were detached using 5 mM EDTA in PBS.
Flow cytometry. Samples were analyzed using a FACSCanto flow cytometer (BD Biosciences) with 
FACSDiva software (BD Biosciences). At least 10,000 events were collected per sample and data were 
analyzed using FlowJo software (TreeStar). Antibodies used for flow cytometry were: MPO (clone 5B8, 
BD Biosciences), CD14 (clone M5E2, BD Biosciences), CD11b (clone D12, BD Biosciences), CD80 (clone 
2D10, Biolegend), CD206 (clone 15-2, Biolegend), and TopFluor-E06 (Avanti Polar Lipids). For E06 stain-
ing, DAPI was used to exclude dead cells.
CD4+ T cell stimulation. T cells were activated in 48-well plates coated with antibodies against CD3 (2 
μg/ml, clone OKT-3, produced in house from a hybridoma line) and CD28 (2 μg/ml, clone CD28.2, BD 
Biosciences). The medium was the same composition as the monocyte medium. A final concentration 
of  10 U/ml recombinant IL-2 was added. Supernatants from the monocyte-to-macrophage differentiated 
cells were used at a ratio of  2:1 with the T cells. Supernatants were harvested at days 3 and 5 to assay the 
cytokine profile.
Cytokine assays and ELISAs. Th1, Th2, and Th17 cytokines were measured with a Cytokine Bead Array 
(BD Biosciences) using a FACScalibur (BD Biosciences) and analyzed using CellQuest Pro. IL-1β, IL-8, 
MIP-1α, CSF-1, and TGF-β levels were measured by ELISA (R&D Systems DuoSet) according to the 
manufacturer’s instructions.
Microarray experiments. RNA was isolated from 5 × 105 monocytes incubated with 100 ng/ml LPS (from 
Escherichia coli, O55:B5, Sigma-Aldrich, L6529) and MPO-ANCA or control IgG (250 μg/ml) for 6 hours 
using a Qiagen Allprep kit according to the manufacturer’s instructions. Potential genomic DNA con-
tamination was removed by Turbo DNase treatment (Ambion/Life Technologies). Total RNA (5 ng per 
sample) was amplified and reverse transcribed and labeled using an Ovation Pico WTA System V2 and 
Encore BiotinIL Kits (NuGen Inc.). The cDNA was hybridized to Illumina HT12V4 microarrays, scanned 
using an Illumina iScan System, and subjected to quantile normalization within the Genome Studio Suite 
v1.0 (Illumina). Expression data were analyzed using Genomics Suite (Partek Inc.) version 6.6, IPA (Qia-
gen), and GSEA (Broad Institute of  MIT and Harvard). All original microarray data were deposited in the 
NCBI’s Gene Expression Omnibus (GEO GSE89153).
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Cellular lipid extraction. Monocytes from a healthy donor were incubated with anti-MPO or control 
IgG for 18 hours as described above (3 × 106 cells/condition). The cell pellets were washed and stored 
at –80°C. All organic solvents used were of  HPLC grade. Extraction of  phospholipids was performed 
using a double-extraction technique by addition of  0.5 ml ice-cold methanol containing 0.005% butylated 
hydroxytoluene and 0.5 ml ultra-high-purity water. The sample was vortexed and 100 μl of  a 1 μg/ml 
solution of  1,2-ditridecanoyl-sn-glycero-3-phosphocholine (13:0, 13:0 PC) in methanol containing 0.005% 
butylated hydroxytoluene was added to each sample. The samples were sonicated at 4°C for 15 minutes. 
Chloroform (500 μl) was added and the samples were sonicated further as described above. The samples 
were then centrifuged for 5 minutes at 14,500 g and the upper aqueous phase was removed and re-extracted 
as above. Both organic phases (bottom layer) were combined, dried under a stream of  oxygen-free nitrogen, 
and stored at –80°C. Before analysis, the extracts were reconstituted in 0.2 ml methanol/chloroform (1:1).
Phospholipid analysis by LCMS. Phospholipids were separated by reverse phase chromatography on an 
HLPC system (Dionex Ultimate 3000) controlled by Chromoleon software, using a Proswift RP-4H col-
umn (1 mm × 250 mm) at room temperature. The eluents used were (A) aqueous 0.1% formic acid con-
taining 5 mM ammonium formate and (B) methanol containing 0.1% formic acid and 5 mM ammonium 
formate. The LCMS run time was 50 minutes with a chromatographic gradient of  70% B from 0 to 4 
minutes, followed by a 3-step gradient increase to 80% B at 8 minutes, 90% B at 15 minutes, and 100% B at 
20 minutes. The gradient was maintained at 100% B until 38 minutes and then decreased back to 70% B by 
50 minutes. The flow of  the mobile phase was set to 50 μl/minute. Samples were diluted 5-fold or 10-fold 
in the starting solvent and 10 μl was loaded onto the column. The phospholipids were detected using tar-
geted and data-dependent scanning routines performed on an AB SCIEX 5500 QTrap mass spectrometer 
controlled by Analyst software. Precursor ion scanning (PIS) of  184 Da was carried out over the mass range 
400–1,000 Da to identify PC and oxidized PC. The declustering potential was set to 50 V for all scans and 
collision energy for PIS was set to 45 eV. Information-dependent data acquisition (IDA) was used to collect 
MS/MS data based on the following criteria: the most intense ion with +1 charge and minimum intensity 
of  1,000 cps was chosen for analysis, using dynamic exclusion for 20 seconds after 2 occurrences and a 
fixed collision energy setting of  47 eV. Other source parameters were adjusted to give optimal response 
from the direct infusion of  a dilute solution of  standards.
Data analysis was performed manually using Peakview 2.0 software by generating XICs for individual 
m/z ratios corresponding to different modified and unmodified phospholipid species and calculating peak 
area. The peak area was normalized to that of  the internal standard to check for extraction variability, but 
subsequently the signal intensities were expressed as a percentage of  the intensity of  the dipalmitoyl PC at 
m/z 734 to take into account variability in the total phospholipid present in the samples.
Reverse transcription quantitative PCR (RT-qPCR). RNA was isolated from monocytes incubated with 
MPO-ANCA or control IgG ± LPS for 18 hours using a Qiagen RNeasy mini kit according to the manu-
facturer’s instructions. RNA (200 ng) was converted to cDNA using a RevertAid H Minus kit (Thermo 
Fisher Scientific) and stored at –80°C. Hydrolysis probes (TaqMan) were used (Thermo Fisher Scientific). 
The first strand cDNA obtained was amplified using the recommended TaqMan primer/probe master-
mix in 384-well plates using the ABI Prism 7900 HT Sequence Detection System (Applied Biosystems) 
in duplicate. The sequence detector SDS 2.4 software (Applied Biosystems) was used to export the Ct 
values (threshold cycle). The reference gene bGus was used as an endogenous control. The comparative Ct 
method was used (2–ΔΔCt) for quantification.
Statistics. Prism (GraphPad software) was used for statistical analysis, with statistical tests used indi-
cated in the figure legends. Some data were logarithmically transformed before analysis if  the variances 
of  the groups were significantly different. Differences were considered significant if  P was less than 0.05. 
Where a Student’s t test was used it was 2 tailed.
Study approval. Blood samples from patients and healthy donors were taken following informed consent 
with ethical approval (NRES committee London—London Bridge 09/H084/72).
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